ExAdEx-Innov at the 2025 Nordic Life Science Mission
2025-10-20
Our journey as part of the French biotech delegation during the Nordic Biotech Mission, organized by Business France Nordics and Bpifrance in Sweden and Denmark,
The poster showcases RES-010, a novel antisense oligonucleotide developed by Resalis Therapeutics to inhibit miR-22, an important post-transcriptional regulator of metabolic pathways in adipose tissue.
In multiple preclinical models—including our ExAdEx human 3D adipose tissue models derived from relevant donor profiles—miR-22 inhibition resulted in the activation of mitochondrial function and browning of white adipose tissue (WAT), supporting a new paradigm in obesity therapy focused on increasing energy expenditure rather than suppressing appetite.
We provided highly clinically relevant 3D human adipose tissue models, derived from donors with obesity, enabling direct validation of RES-010’s efficacy in translationally relevant human systems. These ex vivo tissue models revealed robust mitochondrial activation, enhanced oxygen consumption, and induction of key markers associated to browning and thermogenesis and (UCP1, TOMM20) following miR-22 targeting.
This research underscores the power of combining cutting-edge RNA therapeutics with proprietary human tissue-based technologies to accelerate clinically meaningful obesity solutions.
OBESITY WEEK 2025WHEN: November 5, 2025 / 2:30pm-3:30pm
WHERE: Atlanta (USA)
SESSION: Track 1 – Metabolism and Integrative Physiology
POSTER: #361 – Targeting miR-22 for Sustained Weight Loss: Preclinical Translational Evidence for Obesity Therapy
For more details or to meet the team at the conference, please visit Resalis Therapeutics website: https://www.resalistherapeutics.com
Our journey as part of the French biotech delegation during the Nordic Biotech Mission, organized by Business France Nordics and Bpifrance in Sweden and Denmark,
EXADEX-INNOV Selected for the L’Oréal Innovation Village at WC13, taking place in Rio de Janeiro, August 31-September 4, 2025 ExAdEx-Innov has been selected as
EXADEX-INNOV will be participating in the 35th IFSCC Congress, the world’s premier cosmetic science congress, taking place in Cannes from September 15–18, 2025 VISIT
Copyright © 2022 ExAdEx-Innov All rights reserved
KOL on adipose tissue biology.
Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice).
Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program).
Co-inventor of 5 patents
Expert in clinical applications of adipose tissue.
Plastic Reconstructive and Aesthetic Surgeon in Nice.
Member of the Medical Council of Alpes Maritimes region.
Expert for the French National Regulatory Agency ANSM for medical devices.
Certified by French Health Autority HAS (2020-2024).
PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.
Expert in cell therapy and immunology.
Senior Lecturer (Maitre de conférences).
Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).
Director of « Micoralis » research team at Université Côte d’Azur (Nice).
Founder and CEO of the biotech company Biointerférence (2003-2006).
Co-inventor of 5 patents.
Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.
With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov.
In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille).
He is co-inventor of the 2 company’s patent families.
Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue.
Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.
With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years.
He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.
Main areas of expertise: Biotech Startup Business Development; Project management